Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Metabolite Profiling of [14C]-MD1003 in Healthy Male Subjects
NCT04223232Phase 1Completed
- Sponsor
- MedDay Pharmaceuticals
- Start
- Dec 2019
- Primary completion
- Jan 2020
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of biotin in multiple sclerosis (MS), sponsored by MedDay Pharmaceuticals. Primary endpoints: Mass Balance Recovery of Total Radioactivity: CumAe (Urine), Mass Balance Recovery of Total Radioactivity: Cum%Ae (Urine) and 3 more. Started Dec 2019; status: completed.
02
Drugs
biotin
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04223232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04223232.